Full Press Release Details
ProMIS Neurosciences
Announces Third Quarter 2022 Financial Results and Recent Highlights
US$7.4 million private placement
Gail Farfel, Ph.D., as Chief Executive Officer
progress toward investigational new drug (IND) submission for PMN310 in Alzheimer's disease
Ontario and CAMBRIDGE, Massachusetts - November 14, 2022 - ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN),
a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic misfolded proteins implicated
in the development of neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple
system atrophy (MSA), today announced its third quarter 2022 financial results and recent highlights.
"We continue to progress our therapeutic antibodies selective
for toxic oligomers that are associated with the development and progression of neurodegenerative and other misfolded protein diseases.
We are excited that our lead compound, PMN310, is advancing toward clinical stage development. Most notably, we recently closed a $7.4
million private placement, which will be used to advance PMN310 into a first-in-human study. We anticipate enrolling the first subject in the first half of 2023," said Gail Farfel, Ph.D., Chief Executive Officer of ProMIS Neurosciences. "We believe
our novel discovery platform gives us the potential to advance differentiated next-generation products to address urgent unmet medical
needs as in ALS and MSA, and we are excited to continue our transition toward a clinical phase biotechnology company."
Recent Highlights and Anticipated Milestones
Alzheimer's Disease Program (PMN310)
PMN310, ProMIS's lead compound, is a novel
monoclonal antibody that is highly selective for toxic oligomers of amyloid-beta that are believed to be a major driver of AD.
Third Quarter Financial Highlights
About ProMIS Neurosciences Inc.
ProMIS Neurosciences Inc. is a development
stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers
implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD),
amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company's proprietary target discovery engine is
based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform -
ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of
misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. ProMIS has offices in Toronto, Ontario and Cambridge, Massachusetts. ProMIS is listed on Nasdaq and the Toronto Stock
Exchange under the symbol PMN.
the TSX nor Nasdaq has reviewed and neither accepts responsibility for the adequacy or accuracy of this release. Certain
information in this news release constitutes forward-looking statements and forward-looking information (collectively,
"forward-looking information") within the meaning of applicable securities laws. In some cases, but not
necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as
"plans", "targets", "expects" or "does not expect", "is expected",
"an opportunity exists", "is positioned", "estimates", "intends",
"assumes", "anticipates" or "does not anticipate" or "believes", or variations of
such words and phrases or state that certain actions, events or results "may", "could",
"would", "might", "will" or "will be taken", "occur" or "be
achieved". In addition, any statements that refer to expectations, projections or other characterizations of future
events or circumstances contain forward-looking information. Specifically, this news release contains forward-looking
information relating to targeting of toxic misfolded proteins that may directly address fundamental AD pathology (including that
toxic oligomers of amyloid-beta are a major driver of AD) and have greater therapeutic potential due to reduction of
off-target activity, the initiation of the Company's first-in-human study in 2023, ProMIS' pipeline, the use of net
proceeds of the PIPE, management's belief that its patented platform technology has created an antibody candidate specific to
toxic misfolded oligomers known to be present in Alzheimer's disease, which may have greater therapeutic potential due to
off-target activity, management's anticipated timing of enrollment of the first subject in our Phase 1a
trial in the first half of 2023, the progression of earlier stage antibody candidates for ALS (PMN267) and MSA (PMN442).
Statements containing forward-looking information are not historical facts but instead represent management's current
expectations, estimates and projections regarding the future of our business, future plans, strategies, projections,
anticipated events and trends, the economy and other future conditions. Forward-looking information is necessarily based on a
number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release,
are subject to known and unknown risks, uncertainties and assumptions and other factors that may cause the actual results,
level of activity, performance or achievements to be materially different from those expressed or implied by such
forward-looking information. Important factors that could cause actual results to differ materially from those indicated in the
forward-looking information include, among others, the factors discussed throughout the "Risk Factors" section of the
Company's most recently filed annual information form available on www.SEDAR.com, and in Item 1A of each of its Form 10
Registration Statement and its Quarterly Report on Form 10-Q for the quarters ended June 30, 2022 and September 30, 2022, each
as filed with the Securities and Exchange Commission. Except as required by applicable securities laws, the Company undertakes
no obligation to publicly update any forward-looking information, whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or otherwise.
Condensed Consolidated Balance Sheets
(in US dollars, unless otherwise indicated)
| September 30, 2022 | December 31, 2021 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash | $ | 3,920,742 | $ | 16,943,905 | ||||
| Short-term investments | 30,539 | 33,248 | ||||||
| Prepaid expenses and other current assets | 1,407,864 | 737,316 | ||||||
| Total current assets | 5,359,145 | 17,714,469 | ||||||
| Property and equipment, net | 788 | 4,671 | ||||||
| Intangible assets, net | 21,732 | 27,614 | ||||||
| Total assets | $ | 5,381,665 | $ | 17,746,754 | ||||
| Liabilities and Shareholders' Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,794,807 | $ | 408,981 | ||||
| Accrued liabilities | 1,303,908 | 520,093 | ||||||
| Total current liabilities | 3,098,715 | 929,074 | ||||||
| Convertible debt, net of issuance costs and debt discount | - | 3,906,057 | ||||||
| Derivative liability | - | 5,379,878 | ||||||
| Warrant liability | 1,553,186 | 1,871,687 | ||||||
| Total liabilities | 4,651,901 | 12,086,696 | ||||||
| Commitments and contingencies (Note 13) | ||||||||
| Shareholders' equity: | ||||||||
| Series 1 Convertible Preferred Shares, no par value, 70,000,000 shares authorized, 70,000,000 and 0 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively | - | - | ||||||
| Common Shares, no par value, unlimited s hares authorized, 7,195,529 shares issued and outstanding as of September 30, 2022 and December 31, 2021 | - | - | ||||||
| Additional paid-in capital | 73,988,039 | 68,039,178 | ||||||
| Accumulated other comprehensive loss | (270,316 | ) | (187,919 | ) | ||||
| Accumulated deficit | (72,987,959 | ) | (62,191,201 | ) | ||||
| Total shareholders' equity | 729,764 | 5,660,058 | ||||||
| Total liabilities and shareholders' equity | $ | 5,381,665 | $ | 17,746,754 |
PROMIS NEUROSCIENCES INC.
Condensed Consolidated Statements of Operations
Comprehensive Loss (expressed in US dollars,
except share and per share amounts)
| For the Three Months Ended | For the Three Months Ended | For the Nine Months Ended | For the Nine Months Ended | |||||||||||||
| September 30, | September 30, | September 30, | September 30, | |||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 4,570,562 | $ | 805,392 | $ | 9,702,978 | $ | 1,779,285 | ||||||||
| General and administrative | 1,483,573 | 1,265,486 | 5,154,324 | 1,964,978 | ||||||||||||
| Total operating expenses | 6,054,135 | 2,070,878 | 14,857,302 | 3,744,263 | ||||||||||||
| Loss from operations | (6,054,135 | ) | (2,070,878 | ) | (14,857,302 | ) | (3,744,263 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest expense, net | - | (140,912 | ) | (282,064 | ) | (276,317 | ) | |||||||||
| Change in fair value of financial instruments | 61,407 | 997,095 | 2,972,272 | (3,526,590 | ) | |||||||||||
| Gain on extinguishment of convertible debt and derivative liability | - | - | 1,307,421 | - | ||||||||||||
| Other income/(expense) | 35,853 | 4,052 | 62,915 | 1,673 | ||||||||||||
| Total other income (expense), net | 97,260 | 860,235 | 4,060,544 | (3,801,234 | ) | |||||||||||
| Net loss | (5,956,875 | ) | (1,210,643 | ) | (10,796,758 | ) | (7,545,497 | ) | ||||||||
| Other comprehensive gain/(loss): | ||||||||||||||||
| Gain/(loss) on foreign currency translation | (131,874 | ) | 42,659 | (82,397 | ) | (102,558 | ) | |||||||||
| Comprehensive loss | $ | (6,088,749 | ) | $ | (1,167,984 | ) | $ | (10,879,155 | ) | $ | (7,648,055 | ) | ||||
| Net loss per Common Share, basic and diluted | $ | (0.85 | ) | $ | (0.20 | ) | $ | (1.51 | ) | $ | (1.44 | ) | ||||
| Weighted-average Common Shares, basic and diluted | 7,195,529 | 5,919,485 | 7,195,529 | 5,310,483 |
For further information:
For media inquiries, please contact:
For Investor Relations, please contact:
Stern Investor Relations
Suzanne Messere, Managing Director